keyword
MENU ▼
Read by QxMD icon Read
search

Hairy cell leukemia

keyword
https://www.readbyqxmd.com/read/29770206/recent-advances-in-understanding-and-managing-hairy-cell-leukemia
#1
REVIEW
Tobias Roider, Brunangelo Falini, Sascha Dietrich
Hairy cell leukemia is a rare B-cell malignancy that is characterized by an indolent course. It was initially described as a distinct entity in 1958. Before the establishment of modern treatment, median survival was only 4 years. Since then, major advances in the treatment and understanding of the biology and genomic landscape of hairy cell leukemia have been made. This review summarizes the present understanding of hairy cell leukemia with particular focus on the development of novel and targeted approaches to treatment...
2018: F1000Research
https://www.readbyqxmd.com/read/29742076/update-on-hairy-cell-leukemia
#2
Robert J Kreitman, Evgeny Arons
Hairy cell leukemia (HCL) is a chronic B-cell malignancy with multiple treatment options, including several that are investigational. Patients present with pancytopenia and splenomegaly, owing to the infiltration of leukemic cells expressing CD22, CD25, CD20, CD103, tartrate-resistant acid phosphatase (TRAP), annexin A1 (ANXA1), and the BRAF V600E mutation. A variant lacking CD25, ANXA1, TRAP, and the BRAF V600E mutation, called HCLv, is more aggressive and is classified as a separate disease. A molecularly defined variant expressing unmutated immunoglobulin heavy variable 4-34 (IGHV4-34) is also aggressive, lacks the BRAF V600E mutation, and has a phenotype of HCL or HCLv...
March 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29702524/genetic-convergence-of-rare-lymphomas
#3
Jennifer R Shingleton, Sandeep S Dave
PURPOSE OF REVIEW: We review the genetic foundations of different rare lymphomas to examine their shared origins. These data indicate the potential application of genomics to improve the diagnosis and treatment of these rare diseases. RECENT FINDINGS: Next generation sequencing technologies have provided an important window into the genetic underpinnings of lymphomas. A growing body of evidence indicates that although some genetic alterations are specific to certain diseases, others are shared across different lymphomas...
April 26, 2018: Current Opinion in Hematology
https://www.readbyqxmd.com/read/29693079/schnitzler-syndrome-associated-with-hairy-cell-leukemia-presenting-with-chronic-urticaria-and-arthralgias
#4
Hélène Fank, Jo Caers, Michel Lambert, Liliane Marot, Laurence De Montjoye, Dominique Tennstedt, Marie Baeck, Valérie Dekeuleneer
No abstract text is available yet for this article.
May 2018: JAAD Case Reports
https://www.readbyqxmd.com/read/29685423/response-to-the-therapy-in-hairy-cell-leukemia-systematic-review-and-meta-analysis
#5
REVIEW
Iga Andrasiak, Justyna Rybka, Tomasz Wrobel
Hairy cell leukemia is an uncommon chronic B-cell lymphoproliferative disorder. Various treatment options are available. The objective of the study was to evaluate through meta-analysis the pooled proportions of patients responding to each therapeutic agent. We conducted a systematic review and meta-analysis to estimate the pooled response rate to modern hairy cell leukemia therapies. Articles published between January 1992 and August 2017 were identified by searching PubMed, Web of Science, and the Cochrane Library...
March 31, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29685167/neutropenia-caused-by-hairy-cell-leukemia-in-a-patient-with-myelofibrosis-secondary-to-polycythemia-vera-a-case-report
#6
Andreas Hanssønn Habberstad, Hoa Thi Tuyet Tran, Ulla Randen, Signe Spetalen, Ingunn Dybedal, Geir E Tjønnfjord, Anders Erik Astrup Dahm
BACKGROUND: Polycythemia vera is a myeloproliferative disease that sometimes evolves to myelofibrosis, causing splenomegaly and neutropenia. In this case report, we describe a patient with polycythemia vera and unexplained neutropenia who later turned out to also have hairy cell leukemia. CASE PRESENTATION: A middle-aged Caucasian man with polycythemia vera presented to our hospital with chronic mouth ulcers. Later he developed leukopenia and pancytopenia. Bone marrow biopsies showed fibrosis...
April 24, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29651349/-listeria-monocytogenes-infection-in-hairy-cell-leukemia-a-case-report-and-literature-review
#7
James C Barton, Hayward S Edmunds
Listeria monocytogenes infections have been described in patients with diverse types of malignancy, especially leukemia. We report the case of a 65-year-old man with previously untreated hairy cell leukemia characterized by CD5 positivity and trisomy 12 (3% of blood lymphocytes) who developed bacteremia due to L. monocytogenes serotype 1/2b. We summarize clinical features and treatment of this patient and five previously reported patients with hairy cell leukemia who also had L. monocytogenes infections. All six patients were men...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29618685/-splenic-diffuse-red-pulp-small-b-cell-lymphoma-diagnosed-by-splenectomy-initially-mimicking-hairy-cell-leukemia-japanese-variant
#8
Yukika Yamada, Miyoko Miura, Mayu Tagari, Kazuo Oshimi, Tomokazu Shiragata, Wataru Suga, Tatsurou Takahashi, Kazuyoshi Shimizu, Kouichi Ohshima, Keizou Kajiwara
A 62-year-old man presented to the hospital with thrombocytopenia, and splenomegaly was detected. His blood films prepared by natural air drying revealed medium-sized lymphocytes with unevenly distributed large and small villous projections. The cytoplasm was basophilic, nuclei were oval with clumped chromatin, and nucleoli were absent in most cells. Immune phenotypes CD19+, CD20+, CD11c+, FMC7+, IgM+, and Igκ+ were detected. TRAP stain appeared negative, IgH JH chain genes were monoclonally rearranged, and BRAF V600E mutation was not detected...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29606948/concomitant-non-small-cell-lung-cancer-and-hairy-cell-leukemia-in-a-patient-harboring-braf-v600e-mutation-in-both-tissues-a-case-report
#9
Maria Mitsogianni, Nikolaos Mitsimponas, Felipe Crespo, Karl Axel Hartmann, Bernd Klosterhalfen, Sabine Haase, Aristoteles Giagounidis
The BRAF-V600E mutation has been established as a signature alteration occurring almost universally in hairy cell leukemia. Moreover, it can be detected in a small percentage of patients with non-small cell lung cancer. We report the case of a patient with a metastatic BRAF-V600E-mutated lung adenocarcinoma suffering from concomitant hairy cell leukemia. The identification of an identical BRAF mutation in both malignancies raises physiopathological considerations and might offer unique therapeutic strategies for this group of patients...
January 2018: Case Reports in Oncology
https://www.readbyqxmd.com/read/29567884/utility-of-cd200-expression-and-cd20-antibody-binding-capacity-in-differentiating-chronic-lymphocytic-leukemia-from-other-chronic-lymphoproliferative-disorders
#10
R Poongodi, Neelam Varma, Shano Naseem, Bose Parveen, Subhash Varma
Background: Chronic lymphoproliferative disorders (CLPDs) are heterogeneous group of disorders with variable clinical presentations and outcomes. Therefore, accurate classification is crucial for treatment planning. At present, flow cytometry immunophenotyping (FCM-IPT) is a useful tool for diagnosing these diseases. However, overlapping immunophenotypes do exist. Recently, differential expression of CD200 and variation in number of CD20 antibody bound per cell (ABC) in different CLPDs has been reported...
January 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29562470/-cladribine-in-treatment-of-5-patients-with-hairy-cell-leukemia
#11
Z Y Liu, Y Chen, Y B Chen, Z Y Yan, Y Wang, J M Li, H M Sun, S J Zhang
No abstract text is available yet for this article.
March 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29487070/minimal-residual-hairy-cell-leukemia-eradication-with-moxetumomab-pasudotox-phase-i-results-and-long-term-follow-up
#12
Robert J Kreitman, Martin S Tallman, Tadeusz Robak, Steven Coutre, Wyndham H Wilson, Maryalice Stetler-Stevenson, David J FitzGerald, Linda Santiago, Guozhi Gao, Mark C Lanasa, Ira Pastan
Anti-CD22 moxetumomab pasudotox achieved 46% complete remissions (CRs) in previously reported phase I testing in relapsed/refractory hairy cell leukemia (HCL; n=28). The importance of minimal residual disease (MRD) after CR in HCL is unknown. A 21-patient extension cohort received 50 µg/kg every other day for 3 doses in 4-week cycles. These patients plus 12 previously reported at this upper dose level received 143 cycles without dose-limiting toxicity. The combined 33-patient cohort achieved 64% CR and 88% overall response rates, with median CR duration of 42...
February 27, 2018: Blood
https://www.readbyqxmd.com/read/29382643/relative-survival-reaches-a-plateau-in-hairy-cell-leukemia-a-population-based-analysis-in-the-netherlands
#13
LETTER
Avinash G Dinmohamed, Eduardus F M Posthuma, Otto Visser, Arnon P Kater, Reinier A P Raymakers, Jeanette K Doorduijn
No abstract text is available yet for this article.
March 22, 2018: Blood
https://www.readbyqxmd.com/read/29362898/androgen-therapy-for-acute-myeloid-and-hairy-cell-leukemia
#14
REVIEW
Peter H Wiernik
The purpose of this paper is to review the preclinical and clinical rationale for androgen therapy of acute myeloid (AML) and hairy cell leukemia (HCL). A major recent positive study should renew interest in this therapy, which has been reported to be effective in these leukemias for more than 50 years. Hopefully, renewed interest in this approach, which seems promising, will lead to well-designed modern studies that will precisely define a role for androgens in these leukemias. A recent large prospective, randomized study has demonstrated enhanced survival for elderly AML patients who present with WBC counts < 30,000/μL have improved overall survival when androgens are given post-remission, and numerous case reports suggest that androgens frequently restore normal peripheral blood counts in severely pancytopenic patients with HCL...
January 23, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29299182/bendamustine-plus-rituximab-is-an-effective-first-line-treatment-in-hairy-cell-leukemia-variant-a-report-of-three-cases
#15
Andrea Visentin, Silvia Imbergamo, Federica Frezzato, Marco Pizzi, Roberta Bertorelle, Edoardo Scomazzon, Tamara Berno, Marcello Riva, Elisa Piva, Monica Facco, Francesco Piazza, Gianpietro Semenzato, Livio Trentin
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors. HCLv is characterized by unfavorable prognosis, low complete remission rates and limited disease control following classical hairy cell leukemia-based regimens. In this study, we report 3 cases of elderly patients with treatment-naive, TP53 un-mutated HCLv, who were effectively treated with four cycles of bendamustine plus rituximab. The regimen was completed in all the patients with acceptable toxicity...
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29296733/multifocal-brain-involvement-in-a-patient-with-hairy-cell-leukemia-successfully-treated-with-rituximab-and-cladribine
#16
Anamarija M Perry, Kant Matsuda, Vikram Wadhwa, Donna Hewitt, Muhamad Almiski, James B Johnston, Versha Banerji
Brain involvement, although rare, can occur in HCL.The combination of cladribine and rituximab is a highly effective treatment of HCL with brain involvement.
June 13, 2017: Blood Advances
https://www.readbyqxmd.com/read/29282771/consistency-of-the-moreau-cll-score
#17
Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Evarist Feliu, Jordi Junca
BACKGROUND: The Moreau score is essential for the diagnosis of B-cell lymphoproliferative disorders (B-LPD). METHODS: We assessed the consistency of the Moreau score in a series of 138 patients with at least two samples involved by a B-LPD (316 samples) other than germinal center-derived malignancies, hairy cell leukemia, and mantle cell lymphomas. Patients with evidence of two distinct B-LPDs were also excluded. RESULTS: We found 53 inconsistencies in 44 of 138 (32%) patients...
December 28, 2017: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/29238890/real-time-detection-of-braf-v600e-mutation-from-archival-hairy-cell-leukemia-ffpe-tissue-by-nanopore-sequencing
#18
Davide Vacca, Valeria Cancila, Alessandro Gulino, Giosuè Lo Bosco, Beatrice Belmonte, Arianna Di Napoli, Ada Maria Florena, Claudio Tripodo, Walter Arancio
The MinION is a miniaturized high-throughput next generation sequencing platform of novel conception. The use of nucleic acids derived from formalin-fixed paraffin-embedded samples is highly desirable, but their adoption for molecular assays is hurdled by the high degree of fragmentation and by the chemical-induced mutations stemming from the fixation protocols. In order to investigate the suitability of MinION sequencing on formalin-fixed paraffin-embedded samples, the presence and frequency of BRAF c.1799T > A mutation was investigated in two archival tissue specimens of Hairy cell leukemia and Hairy cell leukemia Variant...
February 2018: Molecular Biology Reports
https://www.readbyqxmd.com/read/29223992/controversies-regarding-use-of-myeloid-growth-factors-in-leukemia
#19
REVIEW
Jacqueline N Poston, Pamela S Becker
This review focuses on the data supporting the use of myeloid growth factors (MGFs) in patients being treated for acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and hairy cell leukemia, for which neutropenia is a common complication of treatment. However, due to the lack of randomized trial data or conflicting results of clinical studies, comprehensive guidelines have been difficult to formulate. Moreover, to date, these diagnoses have not been addressed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MGFs...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29199176/retrospective-evaluation-of-hairy-cell-leukemia-patients-treated-with-three-different-first-line-treatment-modalities-in-the-last-two-decades-a-single-center-experience
#20
Şeniz Öngören, Ahmet Emre Eşkazan, Selin Berk, Tuğrul Elverdi, Ayşe Salihoğlu, Muhlis Cem Ar, Zafer Başlar, Yıldız Aydın, Nükhet Tüzüner, Teoman Soysal
OBJECTIVE: In this study, we retrospectively analyzed the clinical outcome, treatment responses, infectious complications, and survival rates of 71 hairy cell leukemia (HCL) cases. MATERIALS AND METHODS: Sixty-seven patients received a first-line treatment and 2-chlorodeoxyadenosine (cladribine-2-CdA) was administered in 31 cases, 19 patients received interferon-alpha (INF-α), splenectomy was performed in 16 cases, and rituximab was used in one. RESULTS: Although the highest overall response rate (ORR) was observed in patients receiving 2-CdA upfront, ORRs were comparable in the 2-CdA, INF-α, and splenectomy subgroups...
December 1, 2017: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
keyword
keyword
83244
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"